Drugs / ZH9
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06181266 | Jan 2024 → Aug 2025 overdue | non-invasive bladder urothelial carcinoma | Prokarium Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04349553 | Dec 2019 → Sep 2020 | bacterial infectious disease | Prokarium Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZH9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04349553 ↗ |
| Known as | S. enterica serovar Typhi ZH9 | “ZH9 is a live attenuated S. enterica serovar Typhi ZH9” NCT06181266 ↗ |
| Modality | Other / unclassified | “a live attenuated S. enterica serovar Typhi ZH9” NCT06181266 ↗ |
| Route | Oral | “ZH9 oral prime followed by ZH9 IVI” NCT06181266 ↗ |